LDLu Deng

Lu Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Deng has a total of 7 co-authors. Here are the top co-authors by number of shared publications:

  • Cai-Xia Li

    Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, China

    1 shared publication
  • Gang Wang

    National Engineering Research Center for Biomaterial, Sichuan University, Chengdu 610065, China

    1 shared publication
  • Lifang Xie

    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China

    1 shared publication
  • Ming Liu

    Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan 610044, China

    1 shared publication
  • Ping Yang

    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China

    1 shared publication
  • Wanling Lu

    National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China

    1 shared publication

Latest Publications

  • Open Access

    Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue

    by Lu Deng, Ping Yang, Caixia Li, Lifang Xie, Wanling Lu, Yanhan Zhang, Ming Liu, Gang Wang

    Daily insulin injection is necessary for the treatment of the insulin-dependent diabetes. However, the process is painful and inconvenient. Accordingly, we have made exploratory efforts to establish an alternative method for continuous insulin supply via intramuscular injection of a designed plasmid encoding the single-strand insulin analogue (SIA), which provides safe, effective and prolonged control of insulin-dependent diabetes. To generate a SIA, a short flexible peptide was alternatively introduced into the natural proinsulin to replace its original long and rigid C-peptide. Then, the synthetic promoter SP301 was used to drive potent and specific expression of SIA in skeletal muscle cells. By combining the Pluronic L64 and low-voltage electropulse (L/E), the specialized gene delivery technique was applied to efficiently transfer the constructed plasmid into skeletal muscle cells via intramuscular injection. Through these efforts, a plasmid-based intramuscular gene expression system was established and improved, making it applicable for gene therapy. The plasmid-expressed SIA showed biological functions that were similar to that of natural insulin. A single L/E-pSP301-SIA administration provided sustained SIA expression in vivo for about 1.5 months. In addition, the diabetic mice treated with L/E-pSP301-SIA were much healthier than those with other treatments. This plasmid-based system was safe for the treatment of diabetes and did not cause immune responses or pathological damage. The results confirmed that, in a mouse model, long-term positive effects were achieved by a single intramuscular L/E-pSP301-SIA injection, which consequently provided reliable experimental basis for its clinical application for the treatment of diabetes mellitus with promising prospects.